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Abstract
We recently showed that Nebivolol, a β-adrenergic receptor (AR) antagonist attenuates 
myocardial oxidative stress and promotes insulin metabolic signaling in 9 week old zucker 
obese (zO) insulin resistant rats.  Here, we demonstrate that Nebivolol suppresses angiotensin 
II type I receptor (AT1R)-mediated signaling in zO hearts as well as in HL-1 cardiomyocytes. 
We treated 9 week old zO and zucker lean rats (zL) with Nebivolol (10 mg/kg/day) via 
osmotic mini pumps for a period of 21 days. Pressure volume studies of zO rats showed 
abnormalities in LV diastolic function with increased static diastolic stiffness and decreased 
myocardial relaxation compared to age matched zL rats, and Nebivolol blunted these effects. 
To investigate the cardioprotective mechanisms of Nebivolol we used a mouse cardiomyocyte 
HL-l cell line. Treatment of cardiomyocytes with angiotensin (Ang) II showed an increase in 
Ang II type 2 receptor (AT2R) protein levels and phosphorylation of Ser2448 of mammalian 
target of rapamycin (mTOR) and Thr389 of p70S6 kinase (S6K-1), and Nebivolol significantly 
reduced these effects. Moreover, a similar trend of increases in the AT2R protein levels 
and phosphorylation of S6K1 and mTOR was observed zO hearts, and these effects were 
significantly ameliorated in ZO rats treated with Nebivolol. Increases in AT2R and reductions 
in S6K1 are known to mitigate maladaptive cardiac remodeling. Taken together, these results 
indicate that Nebivolol treatment may provide a new strategy for targeting Ang II-mediated 
cardiac disorders.
